Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sexually Transmitted Diseases 2020-Mar

Ingenol mebutate gel .05% in the treatment of anogenital warts: a prospective controlled trial comparing it with topical podophyllin solution 25.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Il collegamento viene salvato negli appunti
Mohammad Dadras
Zeinab Bizaval
Mahmood Hoormand
Nikoo Mozafari

Parole chiave

Astratto

Anogenital warts (AGW) are a common therapeutic challenge. All therapies are associated with burning, pain and frustrating high rate of recurrence. The search for a new alternative continues. Recently a diterpene ester extracted from the Euphorbia Peplus plant (Ingenol mebutate (IM)) has been shown to possess activity against anogenital warts.To compare and evaluate the therapeutic efficacy and safety of topical .05% ingenol gel with another herbal extract medication ( topical 25% podophyllin solution) in treatment of AGWs.This was a comparative single blinded non-randomized, 2-arm trial of Ingenol .05% gel versus podophyllin solution 25% administered up to 6 times to patients with AGWs. To evaluate the therapeutic efficacy, the complete clearance rate and recurrence rate were assessed one week and 12 weeks after last treatment respectively. Safety was assessed by occurrence and severity of pain and local skin reaction (LSR).Out of 31 and 36 patients in IM group and podophyllin group who completed the study, initial complete resolution was observed in 20 (64.5%) and 14(38.9%) patients respectively P=0.03. The initial clearance was faster in the IM group (2.00±0.91 weeks) compared with podophyllin group (4.21±1.05 weeks), P= 0.00. After 3 months, recurrence was seen in 13/20 (65.0%) patients in IM group and 6/14 (42.8%) in podophyllin group, P=0.20.The number of patients with complete resolution after 3 months was not different between two groups ( 7/31 in IM group and 8/36 in podophyllin group, P=0.9). The mean±SD severity score for LSR and pain in IM group was 6.65±1.76 and 6.13±2.57 respectively, which was significantly higher than their scores (3.39±1.57 and 2.58±1.38) in podophyllin group P=0.00.IM .05% gel is effective as podophyllin 25% solution in treating AGWs with further benefit of being much more rapid. However, high recurrence rate, sever pain and local skin reaction limit its use.

Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge